Cargando…
Immune checkpoint inhibitor resistance in soft tissue sarcoma
The emergence of immunotherapy as a cancer therapy has dramatically changed the treatment paradigm of systemic cancer therapy. There have been several trials evaluating immune checkpoint blockade (ICI) in soft tissue sarcoma. While there is generally a limited response in sarcoma, a subset of patien...
Autores principales: | Eulo, Vanessa, Van Tine, Brian A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
OAE Publishing Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9255245/ https://www.ncbi.nlm.nih.gov/pubmed/35800372 http://dx.doi.org/10.20517/cdr.2021.127 |
Ejemplares similares
-
Editorial: New therapeutics for soft tissue sarcomas
por: Weetall, Marla, et al.
Publicado: (2023) -
Advances in immune checkpoint inhibitors for bone sarcoma therapy
por: Thanindratarn, Pichaya, et al.
Publicado: (2019) -
Differential quantities of immune checkpoint-expressing CD8 T cells in soft tissue sarcoma subtypes
por: Klaver, Yarne, et al.
Publicado: (2020) -
Characterization of PD-1/PD-L1 immune checkpoint expression in soft tissue sarcomas
por: Hashimoto, Kazuhiko, et al.
Publicado: (2021) -
Efficacy and safety of angiogenesis inhibitors plus immune checkpoint inhibitors in advanced soft tissue sarcoma: a real-world, single-center study
por: Liu, Zengjun, et al.
Publicado: (2023)